{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:13:50Z","timestamp":1790345630236,"version":"4.1.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T00:00:00Z","timestamp":1673654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>There remains a paucity of data regarding the efficacy of immune checkpoint therapy (ICT) combinations \u00b1 vascular endothelial growth factor (VEGF) targeted therapy (TT) in translocation renal cell carcinoma (tRCC).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This is a retrospective study of patients with advanced tRCC treated with ICT combinations at 11 centers in the US, France, and Belgium. Only cases with confirmed fluorescence in situ hybridization (FISH) were included. Objective response rates (ORR) and progression-free survival (PFS) were assessed by RECIST, and overall survival (OS) was estimated by Kaplan-Meier methods.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>There were 29 patients identified with median age of 38 (21-70) years, and F:M ratio 0.9:1. FISH revealed TFE3 and TFEB translocations in 22 and 7 patients, respectively. Dual ICT and ICT + VEGF TT were used in 18 and 11 patients, respectively. Seventeen (59%) patients received ICT combinations as first-line therapy. ORR was 1\/18 (5.5%) for dual ICT and 4\/11 (36%) for ICT + VEGF TT. At a median follow-up of 12.9 months, median PFS was 2.8 and 5.4 months in the dual ICT and ICT + VEGF TT groups, respectively. Median OS from metastatic disease was 17.8 and 30.7 months in the dual ICT and ICT + VEGF TT groups, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In this retrospective study of advanced tRCC, limited response and survival were seen after frontline dual ICT combination therapy, while ICT + VEGF TT therapy offered some efficacy. Due to the heterogeneity of tRCC, insights into the biological underpinnings are necessary to develop more effective therapies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyac262","type":"journal-article","created":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T14:56:03Z","timestamp":1673708163000},"page":"433-439","source":"Crossref","is-referenced-by-count":33,"title":["Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9658-2206","authenticated-orcid":false,"given":"Omar","family":"Alhalabi","sequence":"first","affiliation":[{"name":"The University of Texas, MD Anderson Cancer Center , Houston, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1751-4943","authenticated-orcid":false,"given":"Jonathan","family":"Thouvenin","sequence":"additional","affiliation":[{"name":"Institut de Canc\u00e9rologie des Hospices Civils de Lyon , Lyon , France"},{"name":"Institut de Canc\u00e9rologie Strasbourg Europe (ICANS\/HUS) , Strasbourg , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"N\u00e9grier","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Lyon I, Centre L\u00e9on B\u00e9rard , Lyon , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9410-1368","authenticated-orcid":false,"given":"Yann-Alexandre","family":"Vano","sequence":"additional","affiliation":[{"name":"Ho\u0302pital Europe\u0301en Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP.Centre\u2014Universite\u0301 de Paris , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0046-0969","authenticated-orcid":false,"given":"Luca","family":"Campedel","sequence":"additional","affiliation":[{"name":"AP-HP, Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elshad","family":"Hasanov","sequence":"additional","affiliation":[{"name":"The University of Texas, MD Anderson Cancer Center , Houston, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1906-5704","authenticated-orcid":false,"given":"Ziad","family":"Bakouny","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute , Boston, MA , USA"},{"name":"Brigham and Women\u2019s Hospital , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew W","family":"Hahn","sequence":"additional","affiliation":[{"name":"The University of Texas, MD Anderson Cancer Center , Houston, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Asim","family":"Bilen","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute of Emory University , Atlanta, GA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6505-8308","authenticated-orcid":false,"given":"Pavlos","family":"Msaouel","sequence":"additional","affiliation":[{"name":"The University of Texas, MD Anderson Cancer Center , Houston, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9201-3217","authenticated-orcid":false,"given":"Toni K","family":"Choueiri","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1856-3023","authenticated-orcid":false,"given":"Srinivas R","family":"Viswanathan","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9515-697X","authenticated-orcid":false,"given":"Kanishka","family":"Sircar","sequence":"additional","affiliation":[{"name":"The University of Texas, MD Anderson Cancer Center , Houston, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5734-3480","authenticated-orcid":false,"given":"Laurence","family":"Albiges","sequence":"additional","affiliation":[{"name":"Institut Gustave Roussy , Villejuif , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel G","family":"Malouf","sequence":"additional","affiliation":[{"name":"Institut de Canc\u00e9rologie Strasbourg Europe (ICANS\/HUS) , Strasbourg , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar M","family":"Tannir","sequence":"additional","affiliation":[{"name":"The University of Texas, MD Anderson Cancer Center , Houston, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,1,14]]},"reference":[{"issue":"8","key":"2023050815241831500_CIT0001","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrurol.2014.162","article-title":"Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers","volume":"11","author":"Kauffman","year":"2014","journal-title":"Nat Rev Urol"},{"issue":"1","key":"2023050815241831500_CIT0002","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.juro.2010.08.092","article-title":"Transcription factor E3 and transcription factor EB renal cell carcinomas: clinical features, biological behavior and prognostic factors","volume":"185","author":"Malouf Gabriel","year":"2011","journal-title":"J Urol"},{"issue":"7","key":"2023050815241831500_CIT0003","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/his.13167","article-title":"Incidence, clinicopathological features and fusion transcript landscape of translocation renal cell carcinomas","volume":"70","author":"Classe","year":"2017","journal-title":"Histopathology"},{"issue":"3","key":"2023050815241831500_CIT0004","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.path.2010.06.011","article-title":"Pediatric renal cell carcinoma","volume":"3","author":"Perlman","year":"2010","journal-title":"Surg Pathol Clin"},{"issue":"6","key":"2023050815241831500_CIT0005","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.eururo.2017.06.040","article-title":"Recommendations for the management of rare kidney cancers","volume":"72","author":"Giles","year":"2017","journal-title":"Eur Urol"},{"issue":"9","key":"2023050815241831500_CIT0006","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/annonc\/mdq029","article-title":"Targeted agents in metastatic Xp11 translocation\/TFE3 gene fusion renal cell carcinoma (RCC): a report from the juvenile RCC network","volume":"21","author":"Malouf","year":"2010","journal-title":"Ann Oncol"},{"issue":"22","key":"2023050815241831500_CIT0007","doi-asserted-by":"crossref","first-page":"5219","DOI":"10.1002\/cncr.25512","article-title":"Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma","volume":"116","author":"Choueiri","year":"2010","journal-title":"Cancer"},{"issue":"12","key":"2023050815241831500_CIT0008","doi-asserted-by":"crossref","first-page":"oyac158","DOI":"10.1093\/oncolo\/oyac158","article-title":"Efficacy of cabozantinib in metastatic MiT family translocation renal cell carcinomas","volume":"27","author":"Thouvenin","year":"2022","journal-title":"The Oncologist"},{"issue":"1","key":"2023050815241831500_CIT0009","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s40425-018-0482-z","article-title":"Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders","volume":"6","author":"Boil\u00e8ve","year":"2018","journal-title":"J ImmunoTher Cancer"},{"issue":"9","key":"2023050815241831500_CIT0010","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"issue":"14","key":"2023050815241831500_CIT0011","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"2023050815241831500_CIT0012","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"issue":"14","key":"2023050815241831500_CIT0013","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"issue":"21","key":"2023050815241831500_CIT0014","doi-asserted-by":"crossref","first-page":"JCO.21.01944","DOI":"10.1200\/JCO.21.01944","article-title":"Phase II trial of cabozantinib plus nivolumab in patients with non\u2013clear-cell renal cell carcinoma and genomic correlates","volume":"40","author":"Lee","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"2023050815241831500_CIT0015","doi-asserted-by":"crossref","first-page":"110190","DOI":"10.1016\/j.celrep.2021.110190","article-title":"Integrative clinical and molecular characterization of translocation renal cell carcinoma","volume":"38","author":"Bakouny","year":"2022","journal-title":"Cell Rep"},{"issue":"1","key":"2023050815241831500_CIT0016","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1200\/JCO.19.01882","article-title":"Results of a multicenter phase II study of atezolizumab and bevacizumab for patients with metastatic renal cell carcinoma with variant histology and\/or sarcomatoid features","volume":"38","author":"McGregor","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6","key":"2023050815241831500_CIT0017","doi-asserted-by":"crossref","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J ImmunoTher Cancer"},{"issue":"2","key":"2023050815241831500_CIT0018","doi-asserted-by":"crossref","first-page":"e000891","DOI":"10.1136\/jitc-2020-000891","article-title":"Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial","volume":"8","author":"Motzer","year":"2020","journal-title":"J ImmunoTher Cancer"},{"issue":"1","key":"2023050815241831500_CIT0019","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.1038\/s41467-021-25894-9","article-title":"9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy","volume":"12","author":"Han","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"2023050815241831500_CIT0020","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/s41467-022-29397-z","article-title":"MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers","volume":"13","author":"Alhalabi","year":"2022","journal-title":"Nat Commun"},{"issue":"6278","key":"2023050815241831500_CIT0021","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1126\/science.aad5944","article-title":"Disordered methionine metabolism in MTAP\/CDKN2A-deleted cancers leads to dependence on PRMT5","volume":"351","author":"Mavrakis Konstantinos","year":"2016","journal-title":"Science"},{"issue":"5","key":"2023050815241831500_CIT0022","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/j.athoracsur.2021.08.054","article-title":"Inhibition of cyclin dependent kinase 4\/6 overcomes primary resistance to programmed cell death 1 blockade in malignant mesothelioma","volume":"114","author":"Jang","year":"2021","journal-title":"Ann Thorac Surg"},{"issue":"1","key":"2023050815241831500_CIT0023","doi-asserted-by":"crossref","first-page":"5262","DOI":"10.1038\/s41467-021-25618-z","article-title":"Integrated exome and RNA sequencing of TFE3-translocation renal cell carcinoma","volume":"12","author":"Sun","year":"2021","journal-title":"Nat Commun"},{"issue":"17","key":"2023050815241831500_CIT0024","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1158\/1078-0432.CCR-12-3825","article-title":"Genomic heterogeneity of translocation renal cell carcinoma","volume":"19","author":"Malouf","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2023050815241831500_CIT0025","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/PAP.0000000000000332","article-title":"Chameleon TFE3-translocation RCC and how gene partners can change morphology: accurate diagnosis using contemporary modalities","volume":"29","author":"Tretiakova","year":"2022","journal-title":"Adv Anat Pathol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/5\/433\/50247549\/oyac262.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/5\/433\/50247549\/oyac262.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T16:08:52Z","timestamp":1683562132000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/28\/5\/433\/6987630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,14]]},"references-count":25,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,1,14]]},"published-print":{"date-parts":[[2023,5,8]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyac262","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5,1]]},"published":{"date-parts":[[2023,1,14]]}}}